drugset / Trial / NCT01911936
A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ELGEMTUMAB | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | ELGEMTUMAB | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | ELGEMTUMAB | Monoclonal antibody | 40 mg/kg | Intravenous |